Current issues in dendritic cell cancer immunotherapy.
Dendritic cells (DCs) initiate and direct the immune response. Their inability to detect danger signals from transformed cells and to generate an effective immunological response may allow cells with a malignant phenotype to evolve into cancers. This defect can be corrected for many cancer types and the immune response boosted to eliminate malignant cells by means of DC-based vaccines/therapies. Rapid advances in our understanding of basic DC physiology and improved methods for DC isolation have made clinical application of DC therapy practical, and encouraging phase I/II results are emerging.
López
José Alejandro
JA
Mater Medical Research Institute, South Brisbane, QLD, Australia.
Hart
Derek N J
DN
D000818:Animals; D017951:Antigen Presentation; D018952:Antigens, CD34 / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D001773:Blood Cells / Q000276:immunology; D002465:Cell Movement; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000145:classification / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009000:Monocytes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D018952:Antigens, CD34; D000951:Antigens, Neoplasm